Table 3 Anti-tumor activity of camrelizumab in different dosage groups
Variables | 60 mg (n = 12) | 200 mg (n = 12) | 400 mg (n = 12) | Total (n = 36) |
|---|---|---|---|---|
Best response, n (%) | ||||
PR | 1 (8.3) | 1 (8.3) | 3 (25.0) | 5 (13.9) |
SD | 2 (16.7) | 3 (25.0) | 4 (33.3) | 9 (25.0) |
PD | 7 (58.3) | 7 (58.3) | 5 (41.7) | 19 (52.8) |
Missing | 2 (16.7) | 1 (8.3) | 0 | 3 (8.3) |
ORR, n (%) | 1 (8.3) | 1 (8.3) | 3 (25.0) | 5 (13.9) |
95% CI | 0.2-38.5 | 0.2-38.5 | 5.5-57.2 | 4.7-29.5 |
DCR, n (%) | 3 (25.0) | 4 (33.3) | 7 (58.3) | 14 (38.9) |
95% CI | 5.5-57.2 | 9.9-65.1 | 27.7-84.8 | 23.1-56.5 |
PFS, months, median (95% CI) | 1.8 (1.2-2.3) | 1.7 (1.6-1.8) | 3.5 (0.4-6.6) | 1.8 (1.1-2.4) |
OS, months, median (95% CI) | 7.1 (0-14.6) | 14.8 (3.5-26.1) | 8.7 (4.3-13.1) | 11.1 (6.8-15.4) |